Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.

Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D.

Br J Cancer. 2019 Jan;120(1):57-62. doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31.

2.

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.

Vitale MG, Scagliarini S, Galli L, Pignata S, Lo Re G, Berruti A, Defferrari C, Spada M, Masini C, Santini D, Ciuffreda L, Ruggeri EM, Bengala C, Livi L, Fagnani D, Bonetti A, Giustini L, Hamzaj A, Procopio G, Caserta C, Sabbatini R.

PLoS One. 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642. eCollection 2018.

3.

Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.

Patrone S, Maric I, Rutigliani M, Lanza F, Puntoni M, Banelli B, Rancati S, Angelini G, Amaro A, Ligorio P, Defferrari C, Castagnetta M, Bandelloni R, Mosci C, DeCensi A, Romani M, Pfeffer U, Viaggi S, Coviello DA.

Genes Chromosomes Cancer. 2018 Aug;57(8):387-400. doi: 10.1002/gcc.22541.

PMID:
29689622
4.

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer.

Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petrera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D'Amico M, Mori M, DeCensi A.

Transl Oncol. 2016 Dec;9(6):600-605. doi: 10.1016/j.tranon.2016.08.001. Review.

5.

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.

Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, Bruno S, Curotto A, DeCensi A.

Cancer Prev Res (Phila). 2016 Jun;9(6):437-44. doi: 10.1158/1940-6207.CAPR-15-0345. Epub 2016 Apr 4.

6.

An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.

D'Amico M, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, Gozza A, Zanardi S, Defferrari C, Provinciali N, Campazzi E, Campora S, Paleari L, Marra D, Petrera M, DeCensi A.

Expert Opin Drug Saf. 2014 Nov;13(11):1437-42. doi: 10.1517/14740338.2014.960388. Epub 2014 Sep 16.

PMID:
25224760
7.

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.

Defferrari C, Campora S, D'Amico M, Piccardo A, Biscaldi E, Rosselli D, Pasa A, Puntoni M, Gozza A, Gennari A, Zanardi S, Lionetto R, Bandelloni M, Decensi A.

J Ovarian Res. 2012 Jun 25;5(1):17. doi: 10.1186/1757-2215-5-17.

8.

The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.

Grossi F, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12. doi: 10.1007/s00280-012-1848-4. Epub 2012 Feb 21.

PMID:
22349923
9.

A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).

Belvedere O, Follador A, Rossetto C, Merlo V, Defferrari C, Sibau AM, Aita M, Dal Bello MG, Meduri S, Gaiardo M, Fasola G, Grossi F.

Eur J Cancer. 2011 Jul;47(11):1653-9. doi: 10.1016/j.ejca.2011.03.020. Epub 2011 Apr 20.

PMID:
21514147
10.

Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.

Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, Vinante O, Pronzato P, Pappagallo G.

Oncologist. 2009 May;14(5):497-510. doi: 10.1634/theoncologist.2008-0260. Epub 2009 May 7.

11.

Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.

Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F.

Crit Rev Oncol Hematol. 2008 Dec;68(3):183-96. doi: 10.1016/j.critrevonc.2008.05.002. Epub 2008 Jul 7. Review.

PMID:
18606548
12.

Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.

Grossi F, Aita M, Follador A, Defferrari C, Brianti A, Sinaccio G, Belvedere O.

Oncologist. 2007 Apr;12(4):451-64. Review.

13.

Maintenance chemotherapy in non-small cell lung cancer.

Rinaldi M, Belvedere O, Cauchi C, Defferrari C, Viola G, Grossi F.

Ann Oncol. 2006 Mar;17 Suppl 2:ii67-70. Review. No abstract available.

Supplemental Content

Loading ...
Support Center